You are here

Genentech

Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics

Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics

Endpoints

artificial intelligence

drug development

Genesis Therapeutics

Flag link:

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

Pharmaforum

clinical trials

Flag link:

Months after retiring from Genentech, Michael Varney brings his drug hunting eye to Frazier

Months after retiring from Genentech, Michael Varney brings his drug hunting eye to Frazier

Endpoints

Frazier Healthcare

Flag link:

Genentech pays $200M for Vaccibody's phase 1 cancer vaccine

Genentech pays $200M for Vaccibody's phase 1 cancer vaccine

Fierce Biotech

cancer vaccines

Flag link:

'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups

'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups

Motley Fool

racial diversity

racial discrimination

Flag link:

Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab

Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab

Fierce Biotech

clinical trials

ulcerative colitis

Flag link:

Genentech to eliminate 474 positions

Genentech to eliminate 474 positions

Beckers Hospital Review

Flag link:

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer

BioSpace

clinical trials

Flag link:

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study

Fierce Pharma

immuno-oncology

checkpoint inhibitors

Bristol-Meyers Squibb

Flag link:

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

BioSpace

triple negative breast cancer

clinical trials

Flag link:

Denali scoots past a setback with barely a scratch, quickly calling up a backup Alzheimer’s player on the bench

Denali scoots past a setback with barely a scratch, quickly calling up a backup Alzheimer’s player on the bench

Endpoints

Denali Therapeutics

Flag link:

Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD

BioSpace

clinical trials

wet age-related macular degeneration

Flag link:

Genentech posts long-term data on near-approval Soliris rival

Genentech posts long-term data on near-approval Soliris rival

Fierce Biotech

Flag link:

3 Roche Companies Hope to Make Clinical Trials More Efficient

3 Roche Companies Hope to Make Clinical Trials More Efficient

Medical Devices and Diagnostics Industry

Flatiron Health

Foundation Medicine

clinical trials

Flag link:

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

Pharmaceutical Business Review

metastatic non-small cell lung cancer

Flag link:

Genentech lures Regev from Broad Institute to lead research and early development

Genentech lures Regev from Broad Institute to lead research and early development

Fierce Biotech

Broad Institute

Flag link:

Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma

Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma

Fierce Pharma

Flag link:

Experts float Roche stroke drug Activase as potential COVID-19 therapy

Experts float Roche stroke drug Activase as potential COVID-19 therapy

Fierce Pharma

Flag link:

Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

Motley Fool

clinical trials

Flag link:

Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD

Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD

BioSpace

breakthrough therapy

Flag link:

Pages